A Phase II Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

HPV positive

IRB 23008: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

HPV negative

1st Line

2nd Line

No Trials Currently Available

Post-op Intervention

Surgical

Pre-op Intervention

Non-Surgical

Recurrent Metastatic

Surgery

CROSS-DISEASE TRIALS:

IRB 00021902: IRB# 19992 EAY131 (MATCH)

IRB 00021902:

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

- Cutaneous Squamous Cell Carcinoma
- Salivary Gland Cancer

- 04.26.21

- OHSU CANCER INSTITUTE

- IRB 21257: Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO® Microdosing in Patients with Head and Neck Cancer

- IRB 22805: A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors

- IRB#17753 Keynote 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)